The continuation of the trial following this interim analysis triggers a milestone payment to Oxford BioMedica of E10 million. TroVax is Oxford BioMedica’s novel cancer immunotherapy product, which is being developed in collaboration with sanofi-aventis.
TRIST (TroVax Renal Immunotherapy Survival Trial) is a Phase III trial of TroVax in patients with locally advanced or metastatic clear cell renal carcinoma. The trial is a randomized, placebo-controlled, two-arm study comparing TroVax in combination with standard of care to placebo with standard of care. To date, over 600 patients have been randomized and more than 100 sites in the US, EU and Eastern Europe are recruiting patients.
Alan Kingsman, CEO of Oxford BioMedica, said: “The trial is on track to complete patient enrollment before the end of the first quarter of 2008 and we anticipate final results in 2009. In addition to further progress of the TRIST study in renal cancer, future events will include Sanofi-aventis commencing its planned Phase III trial of TroVax in patients with metastatic colorectal cancer.”